Orasis Pharmaceuticals Ltd

Orasis Pharmaceuticals Ltd, based in Israel, develops innovative ophthalmic solutions to enhance vision. Their primary product, Qlosi™, addresses presbyopia, improving near visual acuity for those affected by age-related vision decline. Founded in 2015, Orasis Pharmaceuticals Ltd focuses on developing ophthalmic treatments to enhance visual capabilities. The company does not have any reported pivots in business strategy or known subsidiaries.

Based in Herzliya, Israel, its founder has not been disclosed. Orasis has completed 4 deals, with its most recent funding round on October 8, 2024, raising USD 68. 00 mn in Series D funding co-led by investors including Johnson & Johnson Innovation and Arboretum Ventures. This latest funding brings the total amount raised by the company to USD 68.

00 mn. Orasis Pharmaceuticals specializes in developing innovative ophthalmic solutions aimed at addressing presbyopia, a common age-related vision condition. Their flagship product, Qlosi™, is designed to combat the gradual loss of the eye's ability to focus on near objects due to aging. Qlosi™ functions by improving near visual acuity, allowing users to comfortably engage in everyday tasks such as reading and using digital devices without the need for cumbersome glasses or invasive procedures.

The product is currently available in the United States through prescription services, including BlinkRx and Medvantx, and serves a substantial customer base of eye care professionals and patients grappling with the challenges of presbyopia. The company is committed to expanding its reach and enhancing the quality of life for nearly 128 million people in the U. S. affected by this condition.

Orasis Pharmaceuticals generates revenue through the sale of its prescription product, Qlosi™, to eye care professionals who then provide it to their patients. The transaction structure operates primarily on a B2B basis, whereby the company partners with pharmacies and retail distributors like BlinkRx and Medvantx to facilitate access to its product. As a prescription-based offering, revenue is derived from transactions where healthcare providers prescribe Qlosi™ to patients, who subsequently purchase it through licensed pharmacies. This direct-to-consumer model ensures that the company maintains a focused approach in reaching its end users while also maximizing its engagement with the healthcare professionals that influence product adoption.

In October 2024, Orasis Pharmaceuticals Ltd raised USD 68. 00 mn in Series D funding to support the commercial launch of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0. 4% for treating presbyopia in adults. The company aims to expand into new markets, seeking to enhance distribution and accessibility of Qlosi™ to a wider customer base.

The recent funding will be utilized to further develop and execute strategies for the product's launch, ensuring comprehensive market penetration.